San Francisco Bay Area biotech has two antibody platforms designed to improve on the potency and safety of bispecifics

Echoing Biohaven’s arrangement with Pfizer, most Inhibrx assets will land in a well-capitalized newco

Plus: Genentech PI3K combo meets PFS endpoint in Phase III and more from ImmunoGen, SpringWorks, Eligo, BrainChild, Axcella, Sanofi, Aqemia and IGM

With expenses climbing, IGM takes $150M up front in Sanofi deal covering six targets, shoulders most costs at the outset

Bispecific antibodies targeting two tumor antigens are picking up steam, and their benefits could extend to ADCs

Next-generation immune cell engagers and bispecific checkpoints gain ground on T cell engagers at AACR21

Debiopharm will bank €188 million ($226.6 million) for pipeline development now that the biotech has partnered lead program xevinapant with Merck KGaA, adding the German biopharma’s

How the cancer center is choosing clinical trial partners and advancing new modalities

Emerging Company Profile: Ireland’s ONK Therapeutics soups up CAR NK cells with TRAIL variants